Incyte (INCY)
(Real Time Quote from BATS)
$63.13 USD
-0.99 (-1.54%)
Updated Sep 24, 2024 10:22 AM ET
3-Hold of 5 3
C Value D Growth F Momentum D VGM
Company Summary
Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.
The company’s hematology and oncology franchise comprises five approved products, which are Jakafi (ruxolitinib), Monjuvi (tafasitamab-cxix), Pemazyre (pemigatinib), Iclusig (ponatinib) and Zynyz (retifanlimab-dlwr), as well as numerous clinical development programs. Incyte has gained exclusive global rights for Monjuvi from MorphoSys AG.
Lead drug Jakafi is a first-in-class JAK1/JAK2 inhibitor, approved in the United States ...
Company Summary
Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.
The company’s hematology and oncology franchise comprises five approved products, which are Jakafi (ruxolitinib), Monjuvi (tafasitamab-cxix), Pemazyre (pemigatinib), Iclusig (ponatinib) and Zynyz (retifanlimab-dlwr), as well as numerous clinical development programs. Incyte has gained exclusive global rights for Monjuvi from MorphoSys AG.
Lead drug Jakafi is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera (“PV”) who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF and post-essential thrombocythemia MF. The drug is also approved in the United States for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.
While Incyte markets the drug in the United States, it is marketed by Novartis as Jakavi outside the country. Jakafi sales totaled $2.6 billion in 2023, contributing 70% to total revenues.
Opzelura, a novel cream formulation of ruxolitinib, was approved by the FDA in September 2021 for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD). Sales of the drug totaled $337.8 million in 2023, up 162% from the 2022 level.
The FDA also approved Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). Novartis has exclusive worldwide development and commercialization rights to Tabrecta and Incyte will receive royalties on sales of the same. Incyte also has a collaboration agreement with Eli Lilly for Olumiant (baricitinib). In June 2018, the FDA approved the 2mg dose of baricitinib as Olumiant for treating adults with rheumatoid arthritis (RA).
Revenues in 2023 totaled $3.7 billion, up 9% from the 2022 level.
General Information
Incyte Corporation
1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803
Phone: 302-498-6700
Fax: 302-425-2750
Email: ir@incyte.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 10/29/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.34 |
Current Year EPS Consensus Estimate | 1.54 |
Estimated Long-Term EPS Growth Rate | 18.80 |
Exp Earnings Date | 10/29/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 64.12 |
52 Week High | 70.36 |
52 Week Low | 50.27 |
Beta | 0.73 |
20 Day Moving Average | 2,083,386.62 |
Target Price Consensus | 72.33 |
4 Week | -1.60 |
12 Week | 5.34 |
YTD | 2.12 |
4 Week | -3.35 |
12 Week | 0.85 |
YTD | -14.82 |
Shares Outstanding (millions) | 192.60 |
Market Capitalization (millions) | 12,349.39 |
Short Ratio | NA |
Last Split Date | 9/1/2000 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 41.61 |
Trailing 12 Months | 65.43 |
PEG Ratio | 2.21 |
vs. Previous Year | -363.64% |
vs. Previous Quarter | -634.21% |
vs. Previous Year | 9.34% |
vs. Previous Quarter | 18.49% |
Price/Book | 4.12 |
Price/Cash Flow | 26.33 |
Price / Sales | 3.20 |
6/30/24 | 0.75 |
3/31/24 | 12.83 |
12/31/23 | 12.56 |
6/30/24 | 0.56 |
3/31/24 | 9.80 |
12/31/23 | 9.64 |
6/30/24 | 1.92 |
3/31/24 | 3.47 |
12/31/23 | 3.55 |
6/30/24 | 1.84 |
3/31/24 | 3.43 |
12/31/23 | 3.36 |
6/30/24 | 0.90 |
3/31/24 | 17.25 |
12/31/23 | 16.42 |
6/30/24 | 2.52 |
3/31/24 | 19.78 |
12/31/23 | 16.17 |
6/30/24 | 9.10 |
3/31/24 | 27.03 |
12/31/23 | 22.57 |
6/30/24 | 15.56 |
3/31/24 | 24.02 |
12/31/23 | 23.16 |
6/30/24 | 2.18 |
3/31/24 | 2.43 |
12/31/23 | 2.53 |
6/30/24 | 0.01 |
3/31/24 | 0.01 |
12/31/23 | NA |
6/30/24 | 0.95 |
3/31/24 | 0.53 |
12/31/23 | NA |